Kinn Patrick M, Chen Derrick J, Gihring Thomas M, Schulz Lucas T, Fox Barry C, McCreary Erin K, Lepak Alexander J
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Clinical Labs - Microbiology, UW Health, Madison, WI, USA; Department of Pharmacy, UW Health, Madison, WI, USA.
Diagn Microbiol Infect Dis. 2019 Mar;93(3):258-260. doi: 10.1016/j.diagmicrobio.2018.09.017. Epub 2018 Oct 4.
The in vitro activity of meropenem-vaborbactam was examined against clinical carbapenem-resistant Enterobacteriaceae isolates collected over 3 years at our medical center. Only 3 KPC-producers were identified. Susceptibility to meropenem-vaborbactam was noted in 15/16 (94%) isolates (MIC 2 mg/L) that were nonsusceptible to meropenem. Meropenem-vaborbactam may have utility at centers where non-KPC-producers are more frequent.
对美罗培南-巴坦制剂的体外活性进行了检测，检测对象为我们医疗中心在3年多时间里收集的临床耐碳青霉烯类肠杆菌科分离株。仅鉴定出3株产KPC酶的菌株。在对美罗培南不敏感的16株分离株中有15株（94%）（MIC为2mg/L）对美罗培南-巴坦制剂敏感。在非产KPC酶菌株更常见的医疗中心，美罗培南-巴坦制剂可能有用。
